| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
Phosphocreatine disodium tetrahydrate targets creatine kinase, the enzyme that catalyzes the reversible phosphorylation of creatine by ATP. As a substrate for creatine kinase, it is involved in the regeneration of ATP from ADP during periods of high energy demand, such as muscle contraction. It serves as a high-energy phosphate reservoir in muscle tissue, providing a rapid source of ATP. Its role in energy metabolism makes it a valuable tool for studying muscle physiology and energy homeostasis. It does not have a specific therapeutic target but is a key metabolite in energy metabolism.
|
|---|---|
| ln Vitro |
Research indicates that Phosphocreatine possesses neuroprotective and renoprotective potential. In terms of neuroprotection, Phosphocreatine (5-20 mM, 24 h) attenuates MGO (Methylglyoxal)-induced PC12 cell damage, inhibits apoptosis [3], and prevents the loss of mitochondrial membrane permeability [3]. Its mechanism of action involves normalizing mitochondrial function and reducing oxidative stress through the Akt-mediated Nrf2/HO-1 pathway [3]. Regarding renoprotection, Phosphocreatine (5-40 mM, 24 h) protects NRK-52E cells from MGO-induced kidney injury in a concentration-dependent manner [4], and its application at 10-40 mM for 4 h inhibits the production of renal oxidative stress metabolites [4].
In vitro, Phosphocreatine disodium tetrahydrate is used as a substrate for the determination of creatine kinase activity. In these assays, the compound is incubated with a biological sample containing creatine kinase, and the production of ATP or creatine is measured. It is also used in studies of muscle contraction and energy metabolism to regenerate ATP. Its primary activity is as a biochemical reagent, not as a pharmacologically active compound. |
| ln Vivo |
In the context of DOX-induced cardiotoxicity, Phosphocreatine treatment (200 mg/kg, i.p., every other day for 7 weeks) attenuated oxidative stress and apoptosis, and rescued myocardial tissue from necroptosis [2]. Additionally, in a diabetic nephropathy model, Phosphocreatine (20-40 mg/kg, i.v., daily for 6 weeks) demonstrated renoprotective effects by preserving renal function in Sprague-Dawley rats [4].
In vivo, Phosphocreatine disodium tetrahydrate plays a critical role in energy metabolism in skeletal muscle. It serves as a high-energy phosphate reservoir, providing a rapid source of ATP for muscle contraction during periods of high energy demand. It is also found in other tissues, including the brain and heart. The compound is not used as a therapeutic agent but is a key metabolite in energy metabolism. |
| Enzyme Assay |
In vitro non-cell enzyme assays for Phosphocreatine disodium tetrahydrate involve measuring creatine kinase activity. The compound is incubated with creatine kinase, ADP, and other cofactors, and the production of ATP is measured using a coupled enzyme assay or HPLC. These assays are used to diagnose creatine kinase deficiency and to study the regulation of energy metabolism.
|
| Cell Assay |
In vitro cell-based assays for Phosphocreatine disodium tetrahydrate are used to study its effects on cellular energy metabolism. Cells are treated with the compound, and parameters such as ATP levels, creatine phosphate levels, and cellular energy status are assessed. These studies help to elucidate the role of creatine phosphate in cellular energy homeostasis.
|
| Animal Protocol |
In vivo animal studies for Phosphocreatine disodium tetrahydrate are typically conducted to study muscle physiology and energy metabolism. Animals are subjected to exercise or other metabolic challenges, and the levels of creatine phosphate in muscle tissues are measured. These studies help to understand the role of creatine phosphate in energy metabolism and muscle function.
|
| ADME/Pharmacokinetics |
Phosphocreatine disodium tetrahydrate has a molecular weight of 327.14 g/mol and a molecular formula of C₄H₈N₃Na₂O₅P·4H₂O. It is also known as Creatine phosphate disodium salt tetrahydrate and Sodium creatine phosphate dibasic tetrahydrate. The compound is soluble in water and should be stored under appropriate conditions, typically at room temperature, protected from moisture. Its stability in solution is good under proper storage conditions.
|
| Toxicity/Toxicokinetics |
Phosphocreatine disodium tetrahydrate is generally considered safe as a biochemical reagent. It is not intended for human therapeutic use without appropriate regulatory approval. Standard laboratory safety precautions should be followed when handling the compound.
|
| References | |
| Additional Infomation |
Phosphocreatine disodium tetrahydrate is a substrate for creatine kinase and is used for ATP regeneration during skeletal muscle contraction. It is primarily found in the skeletal muscles of vertebrates. Not a drug; used as a biochemical reagent and in clinical diagnostics.
|
| Molecular Formula |
C4H13N3NAO6P
|
|---|---|
| Molecular Weight |
253.126052618027
|
| Exact Mass |
327.041
|
| CAS # |
71519-72-7
|
| Related CAS # |
Phosphocreatine disodium;922-32-7;Phosphocreatine;67-07-2;Phosphocreatine dipotassium;18838-38-5;Phosphocreatine disodium hydrate;19333-65-4;18838-38-5;67-07-2;19333-65-4;71519-72-7;922-32-7;
|
| PubChem CID |
121231436
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
15
|
| Complexity |
276
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN(CC(=O)[O-])/C(=N/P(=O)(O)O)/N.O.[Na+]
|
| InChi Key |
DUXMAYWIASUPMV-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C4H10N3O5P.Na.H2O/c1-7(2-3(8)9)4(5)6-13(10,11)12;;/h2H2,1H3,(H,8,9)(H4,5,6,10,11,12);;1H2/q;+1;/p-1
|
| Chemical Name |
sodium;2-[methyl-[(E)-N'-phosphonocarbamimidoyl]amino]acetate;hydrate
|
| Synonyms |
71519-72-7; RefChem:173558; C05FJ8ZUCS; Glycine, N-(imino(phosphonoamino)methyl)-N-methyl-, disodium salt, tetrahydrate; GLYCINE, N-(IMINO(PHOSPHONOAMINO)METHYL)-N-METHYL-, SODIUM SALT, HYDRATE (1:2:4);
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9505 mL | 19.7527 mL | 39.5054 mL | |
| 5 mM | 0.7901 mL | 3.9505 mL | 7.9011 mL | |
| 10 mM | 0.3951 mL | 1.9753 mL | 3.9505 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
